CClinicalTrials.gg
Not yet recruitingNCT07611188REACTION-VADUpdated May 28, 2026

REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices

An interventional study of Remote Physical Conditioning Program (Telerehabilitation) and Usual care. No Remote Monitoring. in Heart Failure, Advanced Heart Failure and Left Ventricular Assist Device, sponsored by Puerta de Hierro University Hospital. Not yet recruiting at 10 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Puerta de Hierro University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Current international guidelines recommend that patients with a heart pump (left ventricular assist device, LVAD) participate in supervised exercise cardiac rehabilitation programs. However, not all patients with a heart pump are able to attend to a supervised program on a daily basis.

The goal of this clinical trial is to determine whether a home-based exercise program helps patients with a heart pump improve their exercise capacity and quality of life, guided by telemedicine tools including a mobile app, smartwatch, and remote medical checkups. The study will also provide information about the safety of this program by monitoring for any issues or symptoms during home activity.

The trial aims to answer the following questions:

  • Does a 12-week remote exercise program improve patients' exercise capacity? This will be measured using the 6-minute walk test and a cardiopulmonary exercise test.
  • Is it safe for patients to follow this exercise plan at home while being monitored through a mobile app and smartwatch?
  • Does the program improve quality of life and reduce feelings of anxiety or depression? This will be assessed using widely validated questionnaires, such as the Kansas City Cardiomyopathy Questionnaire.

Researchers will compare the remote exercise program to standard care, which usually does not include exercise for patients who are unable to attend the hospital daily.

Participants will:

  • Join the study voluntarily after signing a consent form.
  • Be randomly assigned, with a 50% chance of being in either the exercise group (following a structured plan with a mobile app) or the usual care group (receiving general written advice), to see which approach works best for recovery.
  • Follow a 12-week home-based routine if in the exercise group, including warm-up routine, walking or cycling, respiratory exercises, and light strength training, all supported by the mobile app, smartwatch, and professional monitoring.
  • Visit the hospital three times over six months for medical checkups, including walking and exercise tests, blood analyses, and questionnaires about physical and emotional health.
Read the detailed description

Introduction Although cardiac rehabilitation is recommended in patients with a durable Left Ventricular Assist Device (LVAD), approximately 50% of candidates cannot attend in-person programs due to geographical dificulties.

Study Rationale and Design The RE-ACTION-VAD Trial is the first multicenter randomized controlled trial designed to evaluate the efficacy and safety of a remote conditioning exercise program in patients with recent implantation of a durable Left Ventricular Assist Device (LVAD).

A total of 78 patients will be enrolled and randomized in a 1:1 ratio to:

  1. Remote conditioning group: patients will undergo a three-month home-based program including aerobic, resistance, and respiratory training. Follow-up will be conducted through Telemedicine (mobile application and a smart watch); or
  2. Usual care group: patients will receive written general exercise recommendations.

The primary objective is to assess whether there is an improvement in the distance covered on the 6-minute walk test at 6-month follow-up. Secondary objectives include evaluation of safety, and improvements in cardiopulmonary exercise parameters, quality of life questionnaires, frailty scales, and psychological questionnaires.

Intervention Logistics

The 12-week program is divided into an initial educational phase and a remote phase:

  1. Educational Phase (Week 1): Three in-person sessions to train patients on exercise execution, load management, and the use of respiratory devices.
  2. Remote Phase (Weeks 2-12): Individualized home routines including aerobic training, strength training, and respiratory.

Quality Assurance and Monitoring Plan

To ensure the integrity and standardization of the intervention across the 10 participating centers, the following quality measures are implemented:

  • Site Monitoring: The study has contracted a Contract Research Organization (CRO), to perform clinical trial monitoring and auditing over a three-year period.
  • Standardization of Procedures: Researchers from all centers are required to complete a rotation at the Hospital Ramón y Cajal Rehabilitation Unit to unify exercise protocols. Monthly supervision meetings are held to evaluate compliance and resolve clinical doubts.

Safety monitoring board: independent adverse event assessment blinded to the intervention group.

  • Technical Validation: The mobile platform utilized for monitoring holds the requisite certifications, ensuring technical reliability and data security.

Data Management and Registry Procedures

  • Data Entry and Validation: Data is captured using an electronic data capture system. The system includes predefined rules for data ranges and consistency to minimize entry errors.
  • Source Data Verification (SDV): Investigators may cross-reference data from the electronic data capture system with hospital medical records to ensure accuracy, completeness, and representativeness.
  • Data Dictionary: A comprehensive data dictionary is maintained within the study's electronic data management system, encompassing variables such as anthropometric measures, cardiopulmonary exercise test (CPET) parameters (VO₂ peak, VE/VCO₂, RER), 6-minute walk test (6MWT) distance, biomarkers (NT-proBNP, CA125), and validated quality-of-life scales (KCCQ, MLHFQ).
  • Audit Trails: the electronic data capture system provides automated audit logs to track all data manipulations and user activity, ensuring full traceability.

Sample Size Assessment The study is powered to detect a clinically relevant difference of 35 meters in the 6MWT. Based on a standard deviation of 50 meters, an alpha of 0.05, and a power of 80%, 33 patients per group (66 total) are required. To account for an expected 15% dropout rate, the total sample size is set at 78 participants.

Statistical Analysis Plan (SAP) All analyses will follow the Intention-to-Treat (ITT) principle.

  • Continuous Variables: Will be compared using the Student's T-test for independent samples or the Mann-Whitney U-test for non-parametric data.
  • Categorical Variables: Will be analyzed using Chi-square or Fisher's Exact test.
  • Missing Data Plan: While the ITT principle handles participants as randomized, the study also includes monthly supervision to incentivize compliance and minimize missing data.
  • Significance: A p-value \< 0.05 will be considered statistically significant.

Ethics and Confidentiality The protocol was approved by the Hospital Universitario Puerta de Hierro Ethics Committee (PI 143/25). Data is codified, and the link between codes and patient identity is stored in a password-protected offline file. Upon completion, anonymized data will be deposited in the Zenodo repository.

02

Conditions studied

  • Heart Failure
  • Advanced Heart Failure
  • Left Ventricular Assist Device
  • LVAD
  • Cardiac Rehabilitation
  • Telemedicine
  • Remote Exercise
  • Ventricular Assist Device
  • Exercise Training
  • Conditioning Therapy
  • Cardiopulmonary Exercise Test
  • Six Minute Walk Test
  • Quality of Life
  • Telerehabilitation

Browse trials for

Keywords

  • Left Ventricular Assist Device
  • Advanced Heart Failure
  • Heart Failure
  • Cardiac Rehabilitation
  • Remote rehabilitation
  • Telemedicine
  • 6 minute walking test
  • Quality of Life
  • Cardiopulmonary Exercise Test
  • Telerehabilitation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Recent LVAD Implantation (\<6 months)
  • Clinical stability (defined as meeting all of the following criteria): discharge from the LVAD implantation hospitalization, absence of inotropic medication, hemoglobin >9 g/dL, and no active infection.
  • Inability to participate in a supervised rehabilitation program (due to lack of availability, or inability because geographical reasons).

Exclusion criteria

Exclusion Criteria (any):

  • Functional Inability to Perform Cardiopulmonary Exercise Testing
  • Prior Participation in a Supervised Rehabilitation Program (after the LVAD implantation)
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Remote Exercise Training Via Telemedicine

    Warm-up, Respiratory Training, Continuous Aerobic Exercise, and Strength Training. Remote Monitoring via Telemedicine.

    Other: Remote Physical Conditioning Program (Telerehabilitation)

  • Other
    Control Group

    Usual care. General Exercise Recommendations (Written Instructions). No Remote Monitoring.

    Other: Usual care. No Remote Monitoring.

Interventions

  • OtherRemote Physical Conditioning Program (Telerehabilitation)

    The program includes structured warm-up routines, respiratory training, continuous aerobic exercise, and strength training, with remote follow-up conducted via telemedicine.

  • OtherUsual care. No Remote Monitoring.

    General Exercise Recommendations (Written Instructions). No Remote Monitoring.

05

What researchers measure

Primary outcomes

  1. Six-Minute Walk Test (6MWT)

    Difference in walking distance (meters) in the Six-Minute Walk Test (6MWT).

    Time frame: 3 months

Secondary outcomes

  1. Program Safety

    Evaluate program safety: composite of device alarms, driveline infections, device-related thromboembolic or hemorrhagic complications, cardiovascular events, ventricular arrhythmias, and heart failure decompensations.

    Time frame: 6 months

  2. Cardiopulmonary Exercise Test (CPET): peak oxygen consumption (VO₂peak)

    Changes in peak oxygen consumption (VO₂peak measured in ml/kg/m2)

    Time frame: 3 months

  3. Cardiopulmonary Exercise Test (CPET): VE/VO₂ slope

    Changes in submaximal parameters: VE/VO₂ slope (dimensionless ratio)

    Time frame: 3 months

  4. Cardiopulmonary Exercise Test (CPET): oxygen consumption at the first and second ventilatory thresholds

    Changes in submaximal parameters: oxygen consumption at the first and second ventilatory thresholds (measured in ml/kg/min)

    Time frame: 3 months

  5. Cardiopulmonary Exercise Test (CPET): ventilatory equivalents

    Changes in submaximal parameters: ventilatory equivalents (measured in L/min)

    Time frame: 3 months

  6. Cardiopulmonary Exercise Test (CPET): Oxygen Uptake Efficiency Score (OUES)

    Changes in submaximal parameters: The oxygen uptake efficiency slope (OUES) was calculated from the linear relationship between VO₂ and log₁₀VE and is expressed in mL·min-¹/log(L·min-¹).

    Time frame: 3 months

  7. Cardiopulmonary Exercise Test (CPET): Respiratory Exchange Ratio

    Changes in submaximal parameters: Respiratory Exchange Ratio (RER). The respiratory exchange ratio (RER) was calculated as VCO₂/VO₂ and is reported as a unitless ratio.

    Time frame: 3 months

  8. Cardiopulmonary Exercise Test (CPET): oscillatory patterns

    Changes in submaximal parameters: oscillatory patterns (Yes/No)

    Time frame: 3 months

  9. Quality of life (QoL): Kansas City Cardiomyopathy Questionnaire (KCCQ).

    Changes in quality of life measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). KCCQ is scored from 0 to 100, with higher scores indicating better health status.

    Time frame: 3 months

  10. Quality of life (QoL): Minnesota Living with Heart Failure Questionnaire (MLHFQ).

    Changes in quality of life measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). MLHFQ is scored from 0 to 105, with lower scores indicating better quality of life.

    Time frame: 3 months

  11. Frailty screening (FRAIL scale)

    Frailty screening using the FRAIL scale. FRAIL is scored 0 to 5, with higher scores indicating greater frailty.

    Time frame: 3 months

  12. Fried physical frailty phenotype

    Frailty measured using the Fried Physical Frailty Phenotype. Fried is a score ranging from 0 to 5, with higher scores indicate greater frailty.

    Time frame: 3 months

  13. Psychological changes: depression (Beck Depression Inventory-II).

    Depression symptoms were evaluated by the Beck Depression Inventory-II (BDI-II). BDI-II yields a total score ranging from 0 to 63, with higher scores reflecting greater severity of depressive symptoms.

    Time frame: 3 months

  14. Psychological changes: anxiety (HADS)

    Anxiety symptoms were evaluated using the Hospital Anxiety and Depression Scale (HADS), specifically the anxiety subscale (HADS-A), which yields a score ranging from 0 to 21, with higher scores reflecting greater severity of anxiety.

    Time frame: 3 months

  15. Psychological changes: caregiver burden (Zarit)

    Changes in caregiver burden were evaluated using the Zarit Burden Interview (ZBI), which yields a total score ranging from 0 to 88, with higher scores reflecting greater perceived caregiver burden.

    Time frame: 3 months

  16. Respiratory muscle strength

    Respiratory muscle strength was assessed by measuring maximal inspiratory pressure (MIP) using a handheld device (RP Check, Sibelmed Diagnostics Ltd.). Maximal inspiratory pressure (MIP) is expressed in cmH₂O, with higher values indicating greater inspiratory muscle strength.

    Time frame: 3 months

  17. Prior outcomes in a 6-mont follow-up

    All previously described outcomes will be compared at 6 months after study initiation.

    Time frame: 6 months

Other outcomes

  1. Program Satisfaction and Adherence

    Satisfaction with the program was measured via telemedicine app (daily questionnaires and adherence data).

    Time frame: 6 months

  2. Comparison of Outcomes Between Remote conditioning and Supervised Rehabilitation

    All previously described outcomes will be compared with those of our previous supervised rehabilitation pilot study (REHAB-ASSIST pilot study).

    Time frame: 6 months

  3. Evaluation of Outcomes by Sex and by the aim of LVAD

    All previously described outcomes will be analyzed by subgroups according to sex and the aim of the LVAD

    Time frame: 6 months

06

Study locations

10 sites
  • Hospital Virgen del Rocío
    Seville, Andalusia 41013, Spain
    • Carlos Palacios Castelló, MD · Contact · +34955012000
  • Hospital Universitario de Salamanca
    Salamanca, Castille and León 37007, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Catalonia 03036, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, Catalonia, Spain
  • Complejo Hospitalario Universitario de A Coruña
    A Coruña, Galicia 15006, Spain
  • Complejo Hospitalario Universitario Santiago de Compostela
    Santiago de Compostela, Galicia 15706, Spain
  • Hospital Ramon y Cajal
    Madrid, Madrid 28034, Spain
  • Hospital Clinico San Carlos
    Madrid, Madrid 28040, Spain
  • Hospital 12 de Octubre
    Madrid, Madrid 28041, Spain
  • Hospital Puerta de Hierro
    Majadahonda, Madrid 28028, Spain
    • Mercedes Rivas-Lasarte, MD, PhD · Contact · rivaslasarte@gmail.com · +34911917843
    • Ramon Garrido Gonzalez, MD · Contact
07

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 9, 2025
  • Informed consent form · Jun 9, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Upon completion of the project and publication of the primary analysis, the data will be deposited in the Zenodo repository following appropriate anonymization procedures. The dataset will be accompanied by metadata in Zenodo including: (1) data provenance, (2) patient population characteristics, and (3) a detailed description of the study variables. Access to data stored in the internal repository for other investigators with legitimate scientific interest will be subject to approval by the Ethics Committee. This approach ensures compliance with open-access data requirements applicable to publicly funded research projects, while maintaining data within a controlled environment consistent with their nature as personal data.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

08

Registry details

Key details

Study ID
NCT07611188
Lead sponsor
Puerta de Hierro University Hospital
Collaborators
Carlos III Health Institute
Responsible party
Mercedes Rivas-Lasarte (Cardiologist, MD, PhD, Puerta de Hierro University Hospital) — Principal investigator
First posted
May 28, 2026
Start date
May 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
May 28, 2026

Study contacts

Mercedes Rivas-Lasarte, MD, PhD, Cardiologist
Contact
rivaslasarte@gmail.com
+34911917843
Ramon Garrido Gonzalez, MD, Cardiologist
Contact
ramongarrido15@gmail.com
+34911917843
Mercedes Rivas-Lasarte, MD, PhD
principal investigator · Hospital Puerta de Hierro, Madrid (Spain)
Ramon Garrido Gonzalez, MD
principal investigator · Hospital Puerta de Hierro, Madrid (Spain)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion